

## PRODUCT INFORMATION

<b>Target</b>	IL-28A
<b>Synonyms</b>	Interferon lambda-2;IFN-lambda-2;Cytokine Zcyto20;Interleukin-28A;IL-28A;IFNL2;IL28A;ZCYTO20
<b>Description</b>	Recombinant Human Interferon Lambda-2 is produced by our Mammalian expression system and the target gene encoding Val26-Val200 is expressed with a 6His tag at the C-terminus.
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	Q8IZJ0
<b>Expression Host</b>	HEK293
<b>Tag</b>	C-6×His Tag
<b>Molecular Characterization</b>	Not available
<b>Molecular Weight</b>	20.6 kDa
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE.
<b>Formulation &amp; Reconstitution</b>	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. IL-28A (Interferon-λ2? IFN-λ2), IL-28B/IFN-λ3, and IL-29/IFN-λ1 are type III interferons which are distantly related to IL-10 family and type I IFN family cytokines. Mature human IL-28A is an approximately 22-25 kDa protein that shares 66% amino acid (aa) sequence identity with mouse and rat IL-28A and shows cross-species activity. It shares 96% and 70% aa sequence identity with human IL-28B and IL-29, respectively. IL-28A promotes the Th1 polarization of dendritic cells in the airway and inhibits Th2 and Th17 mediated inflammation. IL-28A additionally exhibits anti-tumor activity, in part by enhancing IL-12 dependent anti-tumor CTL responses <i>in vivo</i> . In contrast, it is up-regulated in invasive bladder cancer where it promotes tumor cell migration.
<b>Background</b>	Research use only
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated






Figure 1. Greater than 95% as determined by reducing SDS-PAGE.

